The company recently announced Q2 results, with essentially no revenue1. And GenomeWeb is reporting that their “broadscale” platform is delayed. I’ve not been keeping track of deadlines on this as my assumption has been that this will come in “this distant future” and I don’t believe we’ve seen any data from this yet…
Anyway… let’s discuss why Nautilus makes me sad.
All Biotechs Are Beautiful
Part of me is sympathetic to any and all Biotech companies. Because Biotech gets such a small slice of the overall funding pie. If we look at all Biotech exits, my estimates suggest we are somewhere in the $300B/yr range:
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.